drugset / Trial / NCT01298505

A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects

NCT01298505

Phase 1 Terminated 36 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study in heathy people is to investigate the safety, toleration and time course of PF-03654764 in the blood, following multiple doses given by mouth together with fexofenadine.

Timeline

Start
2010-06-04
Primary completion
2010-06-04
Completion
2010-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-03654764 Small molecule 2.5 mg Oral
Subject PF-03654764 Small molecule 5 mg Oral
Background Fexofenadine Unknown 60 mg Oral

Indications

No indication recorded.